Innovative Approaches to Retinopathy of Prematurity

Retinopathy of prematurity (ROP) remains a leading cause of childhood blindness worldwide, driven by aberrant vascular development in the retina of preterm infants. Recent advances have shifted the paradigm from solely destructive laser ablation toward precise, minimally invasive and preventive strategies. Artificial intelligence and deep-learning tools now enable automated detection and quantification of disease severity, reducing reliance on limited specialist expertise. Pharmacological interventions, particularly intravitreal injections of vascular endothelial growth factor inhibitors, offer targeted suppression of pathological neovascularisation while preserving more of the native retina. Parallel efforts in molecular nutrition and systemic growth factor modulation seek to restore normal vascular growth during the early, avascular phase of ROP. Finally, individualized risk-prediction models based on birth characteristics and postnatal trajectories promise to optimise screening intervals and resource allocation, especially in low-resource settings. Together, these innovations illustrate a multifaceted approach to preventing vision loss, integrating cutting-edge technology, refined pharmacotherapy and personalised neonatal care.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Innovative Approaches to Retinopathy of Prematurity publication trend

The graph below shows the total number of articles in innovative approaches to retinopathy of prematurity across all publications each year (not limited to Nature Index journals).

Technical terms

Plus disease: A stage of ROP characterised by dilated and tortuous posterior retinal vessels, indicating severe disease needing treatment.

Deep-learning classifier: A neural network model trained to recognise complex patterns in imaging data for automated disease detection.

Intravitreal anti-VEGF therapy: Injection of vascular endothelial growth factor inhibitors into the vitreous to suppress abnormal blood vessel growth.

Neovascularisation: The formation of new blood vessels, which in ROP can be disorganised and vision-threatening.

Phase I ROP: The initial avascular stage of the disease marked by halted physiological vessel growth, preceding pathological neovascularisation.

References

1. Development and international validation of custom-engineered and code-free deep-learning models for detection of plus disease in retinopathy of prematurity: a retrospective study. The Lancet Digital Health (2023).
2. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): five-year outcomes of a randomised trial. EClinicalMedicine (2024).
3. FGF21 via mitochondrial lipid oxidation promotes physiological vascularization in a mouse model of Phase I ROP. Angiogenesis (2023).
4. Individual Risk Prediction for Sight-Threatening Retinopathy of Prematurity Using Birth Characteristics. JAMA Ophthalmology (2020).